Xilio Q2 net loss $15.8M, cash $121.6M; pipeline progress on vilastobart and masked T cell engagers

Xilio Therapeutics, Inc.

2025-Q2 EPS reported -$0.34 vs consensus -$1.13 ▲ beat (+69.9%)

Net loss $15.8M in Q2 2025 vs $13.9M a year ago; cash and equivalents $121.6M vs $55.3M at Dec 31, 2024.
Vilastobart Phase 2 data at ASCO: 26% objective response rate in heavily pre-treated MSS CRC patients without liver metastases.
On track to nominate first development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) in H2 2025.
June 2025 follow-on offering raised ~$50M gross; up to $100M additional from warrants if exercised at $0.75 per share.
Cash runway expected through end of Q3 2026 based on current plans.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.